Literature DB >> 8380079

Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins.

M E Hagensee1, N Yaegashi, D A Galloway.   

Abstract

Vaccinia virus vectors were used to express the major (L1) and minor (L2) capsid proteins of human papillomavirus type 1 (HPV-1) with the vaccinia virus early (p7.5K) or late (pSynth, p11K) promoters. All constructs expressed the appropriate-sized HPV proteins, and both L1 and L2, singly or in combination, localized to the nucleus. Capsids were purified by cesium chloride density gradient centrifugation from nuclei of cells infected with a vaccinia virus-L1 (vac-L1) recombinant or a vac-L1-L2 recombinant but not from vac-L2-infected cells. Electron microscopy showed that the particles were 55 nm in diameter and had icosahedral symmetry. Immunogold-labeled antibodies confirmed the presence of the L1 and L2 proteins in the HPV-1 capsids. Capsids containing L1 alone were fewer and more variable in size and shape than capsids containing the L1 and L2 proteins. The L1-plus-L2 capsids were indistinguishable in appearance from HPV-1 virions obtained from plantar warts. The ability to produce HPV capsids in vitro will be useful in many studies of HPV pathogenicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380079      PMCID: PMC237365     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  High-expression vectors with multiple cloning sites for construction of trpE fusion genes: pATH vectors.

Authors:  T J Koerner; J E Hill; A M Myers; A Tzagoloff
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

2.  Structure of simian virus 40 at 3.8-A resolution.

Authors:  R C Liddington; Y Yan; J Moulai; R Sahli; T L Benjamin; S C Harrison
Journal:  Nature       Date:  1991-11-28       Impact factor: 49.962

3.  New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins.

Authors:  A J Davison; B Moss
Journal:  Nucleic Acids Res       Date:  1990-07-25       Impact factor: 16.971

4.  Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus.

Authors:  S L Hu; B M Travis; J Garrigues; J M Zarling; P Sridhar; T Dykers; J W Eichberg; C Alpers
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

5.  Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system.

Authors:  O Haffar; J Garrigues; B Travis; P Moran; J Zarling; S L Hu
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

Review 6.  Human papillomaviruses and carcinomas.

Authors:  D A Galloway; J K McDougall
Journal:  Adv Virus Res       Date:  1989       Impact factor: 9.937

7.  Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions.

Authors:  N Yaegashi; S A Jenison; J M Valentine; M Dunn; L B Taichman; D A Baker; D A Galloway
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles.

Authors:  P L Winokur; J H McLinden; J T Stapleton
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

9.  Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

Authors:  J Zhou; X Y Sun; D J Stenzel; I H Frazer
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

Review 10.  Human papillomaviruses in the pathogenesis of anogenital cancer.

Authors:  H zur Hausen
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

View more
  111 in total

1.  DNA-induced structural changes in the papillomavirus capsid.

Authors:  C Fligge; F Schäfer; H C Selinka; C Sapp; M Sapp
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment.

Authors:  Hyunwook Lee; Sarah A Brendle; Stephanie M Bywaters; Jian Guan; Robert E Ashley; Joshua D Yoder; Alexander M Makhov; James F Conway; Neil D Christensen; Susan Hafenstein
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Infection with Human Papillomavirus: Update on Epidemiology, Diagnosis, and Treatment.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

4.  Further evidence that papillomavirus capsids exist in two distinct conformations.

Authors:  Hans-Christoph Selinka; Tzenan Giroglou; Thorsten Nowak; Neil D Christensen; Martin Sapp
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

5.  Structural basis of oligosaccharide receptor recognition by human papillomavirus.

Authors:  Jhimli Dasgupta; Malgorzata Bienkowska-Haba; Marcos E Ortega; Hetalkumar D Patel; Sabrina Bodevin; Dorothe Spillmann; Brooke Bishop; Martin Sapp; Xiaojiang S Chen
Journal:  J Biol Chem       Date:  2010-11-29       Impact factor: 5.157

6.  Maturation of papillomavirus capsids.

Authors:  Christopher B Buck; Cynthia D Thompson; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Conserved features in papillomavirus and polyomavirus capsids.

Authors:  D M Belnap; N H Olson; N M Cladel; W W Newcomb; J C Brown; J W Kreider; N D Christensen; T S Baker
Journal:  J Mol Biol       Date:  1996-06-07       Impact factor: 5.469

8.  Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Authors:  Tilo Senger; Lysann Schädlich; Sonja Textor; Corinna Klein; Kristina M Michael; Christopher B Buck; Lutz Gissmann
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

9.  Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals.

Authors:  Jennifer E Cameron; Isaac V Snowhite; Anil K Chaturvedi; Michael E Hagensee
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

10.  Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.

Authors:  Yevgeniy Y Studentsov; Gloria Y F Ho; Morgan A Marks; Robert Bierman; Robert D Burk
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.